NCT03127098View on ClinicalTrials.gov

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

December 7, 2017

Study Completion Date

December 7, 2017

Conditions
Thyroid CancerColon CancerOvarian CancerBreast CancerLung CancerPancreatic Cancer
Interventions
BIOLOGICAL

ETBX-011

ETBX-011 immunization was administered by subcutaneous (SC) injection.

BIOLOGICAL

ALT-803

ALT-803 was administered by SC injection.

Trial Locations (1)

99208

Medical Oncology Associates, Spokane

Sponsors

Lead Sponsor

NantCell, Inc.
All Listed Sponsors
lead

NantCell, Inc.

INDUSTRY

NCT03127098 - QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | Biotech Hunter | Biotech Hunter